Enoxaparin dosing in the elderly using adjusted body weight

Journal of Thrombosis and Thrombolysis

Volumn 28, Issue 3, 2009, Pages 348-353

  Leri, Frederick ^a   Voyce, Stephen J ^a   Scialla, Salvatore ^a   Glavich, William ^a   Dzielak, Edward ^a   Smego Jr , Raymond A ^b   Guzek, John ^b  

^a Moses Taylor Hospital   (United States)

^b Janet Weis Children s Hospital   (United States)

Author keywords

Adjusted dosing; Anti Xa activity; Elderly; Enoxaparin; Low molecular weight heparin

Indexed keywords

BLOOD CLOTTING FACTOR 10A; CREATININE; ENOXAPARIN;

ADJUSTED BODY WEIGHT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DOSE RESPONSE; DRUG DOSE COMPARISON; ELDERLY CARE; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; KIDNEY FUNCTION; MALE; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; BODY WEIGHT; DRUG DOSAGE CALCULATIONS; ENOXAPARIN; FACTOR XA; FEMALE; HEMORRHAGE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; PROSPECTIVE STUDIES; SEX FACTORS;

EID: 70349162437     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-009-0320-8     Document Type: Article

References (25)

1. Yee JYV, Duffull SB (2000) The effect of body weight on dalteparin pharmacokinetics. Eur J Clin Pharmacol 6:293-297. doi: 10.1007/ s002280000141
2. Collignon F, Frydam A, Caplain H et al (1995) Comparison of the pharmacokinectic profiles of three low molecular mass heparins - dalteparin, enoxaparin and nadroparin - administered in healthy volunteers (doses for prevention of thromboembolism). Thromb Haemost 73:630-640
3. Bruno R, Baille P, Retout S et al (2003) Population pharmacokinetics and pharmacodynamics of enoxaparin in unstable angina and non-ST-segment elevation myocardial infarction. Br J Clin Pharmacol 56:407-414. doi: 10.1046/j.1365-2125.2003.01904.x
4. Hirsch J, Raschke R (2004) Heparin and low molecular weight heparin: The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126(3):188S-203S. doi: 10.1378/chest.126.3_suppl.188S
5. Montalescot G, Collet JP, Tanguy ML et al (2004) Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin. Circulation 110:392-398. doi: 10.1161/ 01.CIR.0000136830.65073.C7
6. Lim W, Dentali F, Eikelboom JW et al (2006) Meta-analysis: Low molecular weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med 144:673-684
7. Mammen EF, Arcelus J, Messmore H et al (1999) Clinical differentiation of low molecular weight heparins. Semin Thromb Hemost 25(3):135-144
8. Becker R, Spencer F, Gibson M et al (2002) Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST elevation acute coronary syndromes. Am Heart J 143:753-759. doi: 10.1067/mhj.2002.120774
9. Mahe I, Gouin-Thibalt I, Drouet L et al (2007) Elderly medical patients treated with prophylactic dosages of enoxaparin: Influence of renal function on anti-Xa activity level. Drugs Aging 24:63-71. doi: 10.2165/ 00002512-200724010-00005
10. Campbell NR, Hull RD, Brant R, Hogan DR, Pineo GF (1996) Aging and heparin-related bleeding. Arch Intern Med 156:857-860. doi: 10.1001/ archinte.156.8.857
11. Landefield CS (1987) Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy. Am J Med 82:703-713. doi: 10.1016/ 0002-9343(87)90004-0
12. Antman EM, Morrow DA, McCabe CH et al (2006) Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med 354:1477-1488. doi: 10.1056/NEJMoa060898
13. The Thrombolysis in Myocardial Infarction (TIMI) 11A Trial Investigators (1997) Dose-ranging trial of enoxaparin for unstable angina: Results of TIMT 11A. J Am Coll Cardiol 29:1474-1482
14. Gouin-Thibalt I, Pautas E, Siguret V (2005) Safety profiles of different low molecular weight heparins used at therapeutic dose. Drug Saf 28:333-349. doi: 10.2165/00002018-200528040-00005
15. Hulot JS, Vantelon C, Urien S et al (2004) Effect of renal function on the pharmacokinetics of enoxaparin and consequences of dose adjustment. Ther Drug Monit 26:305-310. doi: 10.1097/00007691-200406000-00015
16. Vitoux JF, Aiach M, Roncato M, Fiessinger JN (1988) Should thromboprophylactic dosage of low molecular weight heparin be adapted to patient's weight? Thromb Haemost 59:120
17. Samama MM, Gerotziafas GT (2000) Comparative pharmacokinetics of LMWHs. Semin Thromb Hemost 26(1):31-38. doi: 10.1055/s-2000-9497
18. Mismetti P, Laporte-Simitsidis S, Navarro C et al (1998) Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (nadroparin). Thromb Haemost 1998:1162-1165
19. Mahe I, Drouet L, Chassany O, Grenard AS, Caulin C, Bergmann JF (2002) Low molecular weight heparin for the prevention of deep venous thrombosis: A suitable monitoring in elderly patients? Pathophysiol Haemost Thromb 32:134-136. doi: 10.1159/000065216
20. Collet JP, Montalescot G, Choussat R, Lison L, Ankri A (2001) Enoxaparin in unstable angina patients with renal failure. Int J Cardiol 80:81-82. doi: 10.1016/S0167-5273(01)00455-7
21. Davy KP, Seals DR (1994) Total blood volume in healthy young and older men. J Appl Physiol 76:2059-2062. doi: 10.1063/1.357639
22. Phillips PA, Johnston CI, Gray L (1993) Disturbed fluid and electrolyte homoeostasis following dehydration in elderly people. Age Ageing 22:S26-S33
23. Lamb EJ, Webb MC, Simpson DE et al (2003) Estimation of glomerular filtration rate in older patients with chronic renal insufficiency: Is the modification of diet in renal disease formula an improvement? J Am Geriatr Soc 51:1012-1017. doi: 10.1046/j.1365-2389.2003.51330.x
24. Van Den Noortgate NJ, Janssens WH, Delanghe R et al (2002) Serum cystatin C concentration compared with other markers of glomerular filtration rate in the old. J Am Geriatr Soc 50:1278-1282. doi: 10.1046/ j.1532-5415.2002.50317.x
25. Fliser D, Bischoff I, Hanses A et al (1999) Renal handling of drugs in the healthy elderly. Eur J Clin Pharmacol 55:205-211. doi: 10.1007/ s002280050619